Can a new injection help tackle obesity? a trial investigates

NCT ID NCT07754474

Not yet recruiting Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This early-stage trial is testing an investigational drug called BI 3034701 in people with overweight or obesity who also have at least one weight-related health condition. The main goal is to see how safe and tolerable the drug is when given by injection, and to understand how it moves through the body. Participants will receive either the drug or a placebo, and the study will compare different ways of adjusting the dose over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BI 3034701, an investigational drug given by injection, compared to placebo
What this could lead to: If successful, this could lead to a new treatment option for weight management in people with overweight or obesity and related health issues.
What could go wrong: This is an early Phase 1 trial with a small number of participants, so safety and effectiveness are not yet established. The drug may cause side effects or may not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OVERWEIGHT

Contacts and locations

Locations

hVIVO Mannheim

Mannheim, 68167, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.